MK-8776

N/A

Report date: 2022/08/29 20:00:24
NME

Base Information

Drug NameMK-8776
Drug Alias NameMK-8776SCH-900776
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCheckpoint kinase 1 inhibitors
TargetsCheckpoint kinase 1
Therapy Area/IndicationsLymphoma, Non-HodgkinHodgkin DiseaseLeukemia, Myelomonocytic, Acute +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme CorpNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteMerck Sharp & Dohme LLC
Active IndicationsN/A
Inactive IndicationsLymphoma, Non-HodgkinHodgkin DiseaseLeukemia, Myelomonocytic, Acute +[10] 

Other Information

ATC CodeN/A
Related LinksN/A